Related Experiment Video

Updated: Jul 2, 2025

External Cephalic Version: Is it an Effective and Safe Procedure?
08:49

External Cephalic Version: Is it an Effective and Safe Procedure?

Published on: June 6, 2020

14.5K

Obstetric and Early Neonatal Outcomes Following Second and Third COVID-19 Vaccination in Pregnancy

Ravit Peretz-Machluf1, Mayan Gilboa2, Shiran Bookstein-Peretz1

  • 1Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

The Israel Medical Association Journal : IMAJ
|February 29, 2024
PubMed

Insights

The COVID-19 booster vaccine (BNT162b2) is safe for pregnant women, showing no increased adverse obstetric or neonatal outcomes. Booster vaccination during pregnancy is associated with fewer urgent cesarean deliveries.

Area of Science:

  • Obstetrics and Gynecology
  • Infectious Diseases
  • Vaccinology

Background:

  • Pregnant individuals face higher risks for severe COVID-19.
  • While data on two COVID-19 vaccine doses exist, information on booster doses in pregnancy is limited.
  • The BNT162b2 (Pfizer/BioNTech) mRNA vaccine is widely used.

Purpose of the Study:

  • To compare obstetric and early neonatal outcomes in pregnant women receiving a COVID-19 booster vaccine versus those with only two doses.
  • To assess the safety and efficacy of the BNT162b2 vaccine booster during pregnancy.

Main Methods:

  • A cross-sectional study compared pregnant women vaccinated with two BNT162b2 doses to those who received a third (booster) dose.
  • Outcomes analyzed included obstetric and early neonatal parameters.

Main Results:

  • 84 pregnant women received the booster dose, and 139 received two doses.
  • The booster group received the vaccine earlier in pregnancy (212 vs. 315 weeks).
  • No significant differences in obstetric or neonatal outcomes were observed, except for lower urgent cesarean delivery rates in the booster group (aOR 0.21, P=0.039).

Conclusions:

  • The BNT162b2 COVID-19 booster vaccine is safe for use during pregnancy.
  • Booster vaccination does not increase the rate of adverse obstetric or early neonatal outcomes.
  • The booster dose may be associated with a reduced need for urgent cesarean deliveries.
Abstract

More Related Videos

Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic PolyI:C07:13

Induction of Maternal Immune Activation in Mice at Mid-gestation Stage with Viral Mimic PolyI:C

Published on: March 25, 2016

18.4K
Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain05:51

Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain

Published on: July 24, 2016

19.5K

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.4K
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
307
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
209
Vaccinations01:51

Vaccinations

Overview
44.5K
Factors Affecting the Risk of Infection01:26

Factors Affecting the Risk of Infection

The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
11.8K